STANT
PrivateLast Round
Seed
Nov 19, 2024
Momentum Score
25 /100
Company Overview
STANT is a biotech company developing proprietary inhibitors of the STING pathway with a unique and differentiated mechanism of action for the treatment of autoimmune, inflammatory, cardiovascular, metabolic and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
STANT Comps
Public and private peers based on sector, stage, and business model.
STANT Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 19, 2024 |
STANT Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Brabantse Ontwikkelings Maatschappij | Seed |
| First Fund | Seed |
STANT Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about STANT's valuation, stock price, and market status.
